TIDMHEIQ
RNS Number : 6117J
HeiQ PLC
14 December 2022
14 December 2022
HeiQ Plc
("HeiQ" or "the Company")
Increased interest in HeiQ Chrisal to 71%
HeiQ Plc (LSE: HEIQ), an established global brand in materials
and textile innovation which operates in high-growth markets, is
pleased to announce that it has increased its interest in HeiQ
Chrisal from 51% to 71%.
On 3 March 2021, HeiQ announced the acquisition of 51% of the
share capital and voting rights of Chrisal N.V., Belgium, now
called HeiQ Chrisal, a biotechnology company and a leader in
innovative ingredients and consumer products that incorporate the
benefits of probiotics and synbiotics.
HeiQ will pay EUR2.9 million for the additional 20% shareholding
to the vendors of Chrisal through the issue of 3,348,164 new
ordinary shares in the Company, at a price of 0.751p per share,
which represents the average 5 day closing price prior to exercise
of the options by HeiQ Chrisal's minority holders. This stake is
valued on the same basis as the initial 51% interest acquired in
HeiQ Chrisal in March 2021. The purchase follows the decision by
four minority shareholders to exercise their option on December
2(nd) to sell their shares to HeiQ.
HeiQ Chrisal is the developer of HeiQ Synbio, one of four
potential blockbuster technologies in HeiQ's portfolio. HeiQ Synbio
allows hospital detergents to become much more effective than the
disinfectants used today. It significantly reduces surface
pathogens and antimicrobial resistance which is particularly
important in hospitals. In H1 2022, HeiQ achieved significant
milestones on the way to establishing synbiotic detergents as a new
standard in hospital cleaning. An independent study by the opinion
leading Charité University Hospital Berlin, and the Robert
Koch-Institute proved synbiotic cleaners far more effective than
disinfectants alone. This positions the HeiQ Synbio platform
ideally, given that upcoming European Union regulations are
expected to favour synbiotic cleaners.
HeiQ co-founder and CEO Carlo Centonze said:
"This deal increases our exposure to the significant potential
upside available from HeiQ Synbio. To have achieved this on the
same valuation terms as our original transaction nearly two years
ago is pleasing, particularly given that since then we have
achieved a major milestones in establishing synbiotic detergents as
a new standard in hospital cleaning.
HeiQ Chrisal continues to provide us with revenue from
additional growth markets as well as multiple cross-selling
opportunities for both Company's core product range. With this in
mind, we are pleased to strengthen our shareholding through this
latest transaction."
Issue of Equity and Total Voting Rights
The Company will issue 3,348,164 new ordinary shares
("Consideration Shares") to the sellers at a price of GBP0.751 per
share, which is the average 5 day closing price prior to option
exercise in order to satisfy the consideration due. Applications
have been made for the Consideration Shares to be admitted to the
standard segment of the Official List, and to trading on the London
Stock Exchange's Main Market ("Admission").
It is expected that Admission will become effective, and that
dealings in the new Ordinary Shares are expected to commence, at
08.00 a.m. on 15 December 2022.
Following Admission, the total number of Ordinary Shares in
issue will be 140,082,472 and the total number of voting rights
will therefore be 140,082,472. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the share capital of the Company
under the FCA's Disclosure and Transparency Rules.
This announcement contains inside information.
For further information, please contact:
HeiQ Plc
Carlo Centonze (CEO) +41 56 250 68 50
Cenkos Securities plc (Joint Broker) +44 (0) 207 397
Stephen Keys / Callum Davidson 8900
------------------
SEC Newgate (Media Enquiries) +44 (0) 20 3757
Elisabeth Cowell / Axaule Shukanayeva 6882
/ Molly Gretton HeiQ@s ecnewgate
.co.uk
------------------
About HeiQ
HeiQ is focused on improving the lives of billions of people
world-wide by innovating the materials people use every day. HeiQ
has strong IP which is at the forefront of global technology in the
$10 billion antimicrobial fabrics market, $24 billion textile
chemicals market, the $50 billion probiotics market and the $150
billion man-made fibers market. It has also moved into the medical
device, healthcare and hygiene coatings markets, to help make
hospitals and healthcare environments more hygienic. HeiQ aims to
deliver growth for its shareholders through a combination of
increased sales of its core products and by entering additional
lucrative markets through disruptive innovations and M&A.
HeiQ has created some of the most effective, durable and
high-performance technologies in the market today, which cool,
warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has
developed over 200 technologies in partnership with 300 major
brands and it has a significant R&D pipeline containing over 50
projects. The Company has won multiple awards and gained a strong
reputation for the ESG & sustainable downstream effect of its
innovations. HeiQ is the only company to have won the Swiss
Technology award twice. It has also won the Swiss Environmental
award with an innovation that saves energy and water consumption
during the textile manufacturing process.
Led by an experienced leadership team, HeiQ researches new
solutions for partners, delivers scaled up manufacturing from its
sites across the world and helps partners market the product to end
consumers - aiming for lab to consumer in months.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACQEAFADFLFAFAA
(END) Dow Jones Newswires
December 14, 2022 02:00 ET (07:00 GMT)
Heiq (LSE:HEIQ)
Historical Stock Chart
From Nov 2024 to Dec 2024
Heiq (LSE:HEIQ)
Historical Stock Chart
From Dec 2023 to Dec 2024
